What the Remaining 2026 Readouts Mean for the Timeline The trials that drive the commercial obesity label are TRIUMPH-1 (general obesity) and TRIUMPH-3 (obesity plus cardiovascular disease)
Ethics declarations Competing interests No writing assistance or financial support was used in the preparation of this article
The 28.7% body weight loss recorded in Phase 3 exceeds every other drug on the market or in testing
However, preliminary data suggests: Tirzepatide: Approximately 33-39% of weight lost was lean mass in SURMOUNT trials Retatrutide: Early data suggests potentially better lean mass preservation, possibly due to glucagon's effects on protein metabolism Regardless of which medication you use, resistance training and adequate protein intake (1.0-1.2g per kg body weight daily) are recommended to minimize muscle loss during treatment
By including "GLP-1" in the product name, Peaka borrows credibility from the pharmaceutical class of GLP-1 receptor agonists that have demonstrated dramatic weight loss results in clinical trials
ZOA gains +19pp, Bang gains +21pp, Reign gains +20pp, PRIME gains +17pp
